| Biotechnology Industry | Healthcare Sector | Mr. Albert Alexander Haeggstrom CEO | XHEL Exchange | FI4000330972 ISIN |
| FI Country | 165 Employees | - Last Dividend | - Last Split | - IPO Date |
Nanoform Finland Oyj is a trailblazer in the field of nanotechnology and drug particle engineering, catering to the pharmaceutical and biotech sectors across Europe and the United States. Since its inception in 2008, the company has been dedicated to revolutionizing the way active pharmaceutical ingredients (APIs) are developed and produced. Headquartered in Helsinki, Finland, Nanoform aims to enhance the efficacy and performance of drugs by leveraging its cutting-edge proprietary technology. The company’s innovative approach to nanoparticle production not only increases the bioavailability of drugs but also opens up new possibilities for drug development and delivery.
Utilizing its proprietary Controlled Expansion of Supercritical Solutions (CESS) technology, Nanoform provides unique nanoparticle production services. This advanced method allows for the precise engineering of drug particles to nanoscale dimensions, resulting in enhanced solubility and bioavailability. This innovative service is tailored to meet the specific needs of clients, aiming to improve the performance and efficacy of their pharmaceutical products.
STARMAP is a cutting-edge, secure online portal offered by Nanoform that enables the performance of a large number of in-silico CESS experiments. This platform allows clients to simulate the nanoparticle engineering process, providing insightful data and predictions on how to optimize drug formulations for better outcomes. STARMAP serves as a powerful tool for accelerating drug development cycles and achieving more predictable and effective results.